FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
Roche announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600…
Read More...
Read More...
